Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Alzinova

0.58 SEK

-1.35 %

Less than 1K followers

ALZ

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-1.35 %
-24.77 %
-29.67 %
-69.60 %
-59.06 %
-79.33 %
-81.16 %
-89.97 %
-91.87 %

Alzinova is a biotechnology company. The company specializes in the therapeutic treatment of Alzheimer's and conducts research and development of peptides that are further developed as vaccines. In addition, the company also develops various research tools within the field of work. The largest operations are found in the Nordic market. The company was founded in 2011 and has its headquarters in Mölndal.

Read more
Market cap
90.01M SEK
Turnover
84.7K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
25/3
2026

Annual report '25

14/5
2026

Interim report Q1'26

26/5
2026

General meeting '26

All
Press releases
3rd party
ShowingAll content types
Press releaseyesterday

Alzinova deltar i flera internationella bransch- och investerarevent under våren och sommaren 2026

Alzinova
Press releaseyesterday

Alzinova to participate in several international industry and investor events during spring and summer 2026

Alzinova
Regulatory press release2/25/2026, 2:12 PM

Alzinova offentliggör slutligt utfall i företrädesemissionen

Alzinova

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2/25/2026, 2:12 PM

Alzinova announces final outcome of the rights issue

Alzinova
Press release2/25/2026, 12:00 PM

DNB Carnegie Access: Alzinova - Beyond plaques: the scientific rationale behind ALZ-101

Alzinova
Regulatory press release2/23/2026, 9:57 PM

Alzinova offentliggör preliminärt utfall i företrädesemissionen

Alzinova
Regulatory press release2/23/2026, 9:57 PM

Alzinova announces preliminary outcome of the rights issue

Alzinova
Regulatory press release2/17/2026, 7:30 AM

Sista dag för handel med uniträtter i Alzinovas företrädesemission

Alzinova
Regulatory press release2/17/2026, 7:30 AM

Last day of trading in unit rights in Alzinovas rights issue

Alzinova
Regulatory press release2/16/2026, 12:00 PM

Alzinova utser internationellt erkänd Alzheimerexpert som Global Principal Investigator inför planerad fas 2-studie

Alzinova
Regulatory press release2/16/2026, 12:00 PM

Alzinova engages renowned international Alzheimer’s expert as Global Principal Investigator ahead of planned Phase 2 study

Alzinova
Regulatory press release2/6/2026, 7:45 AM

Teckningsperioden i Alzinovas företrädesemission av units inleds idag

Alzinova
Regulatory press release2/6/2026, 7:45 AM

The subscription period in Alzinovas rights issue of units starts today

Alzinova
Regulatory press release2/3/2026, 1:50 PM

Alzinova offentliggör prospekt med anledning av företrädesemission av units

Alzinova
Regulatory press release2/3/2026, 1:50 PM

Alzinova publishes prospectus in connection with rights issue of units

Alzinova
Press release1/26/2026, 7:31 AM

Dagens Börs AB: Dagens Börs intervjuar Tord Labuda, VD för Alzinova

Alzinova
Press release1/19/2026, 1:30 PM

Alzinova fördjupade partnerdiskussioner vid J.P. Morgan Healthcare Conference i San Francisco

Alzinova
Press release1/19/2026, 1:30 PM

Alzinova advanced partner discussions at the J.P. Morgan Healthcare Conference in San Francisco

Alzinova
Press release12/30/2025, 7:53 AM

BioStock: Alzinova kommenterar emission om 50 Mkr

Alzinova
Press release12/30/2025, 7:53 AM

BioStock: Alzinova comments on SEK 50 million rights issue

Alzinova
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.